IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, used once daily in basal-bolus treatment with insulin aspart in type 1 diabetes

被引：0
|
作者：
Hirsch, I. [1 ]
Franek, E. [2 ,3 ]
Courreges, J. P. [4 ]
Mersebach, H. [5 ]
Dykiel, P. [6 ]
Bode, B. W. [7 ]
机构：
[1] Univ Washington, Sch Med, Seattle, WA USA
[2] Cent Clin Hosp MSWiA, Warsaw, Poland
[3] Polish Acad Sci, Med Res Ctr, Warsaw, Poland
[4] Gen Hosp, Diabetol & Vasc Dis Unit, Narbonne, France
[5] Novo Nordisk AS, Global Dev, Soborg, Denmark
[6] Novo Nordisk AS, Malmo, Sweden
[7] Atlanta Diabet Associates, Atlanta, GA USA
来源：
DIABETOLOGIA | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1050
引用
收藏
页码：S427 / S427
页数：1
相关论文
共 50 条
  • [1] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: comparison with biphasic insulin aspart 30
    Vaag, A.
    Leiter, L. A.
    Franek, E.
    Weng, J.
    Damci, T.
    Munoz Torres, M.
    Donnet, J. -P.
    Endahl, L.
    Skjoth, T.
    Niskanen, L.
    [J]. DIABETOLOGIA, 2011, 54 : S423 - S423
  • [2] Efficacy and Safety of a New Basal Insulin with a Bolus Boost (IDegAsp) Used Once Daily in Combination with Insulin Aspart (IAsp) in People with Type 1 Diabetes
    Hirsch, Irl B.
    Franek, Edward
    Courreges, Jean-Pierre
    Mersebach, Henriette
    Dykiel, Patrik
    Bode, Bruce W.
    [J]. DIABETES, 2011, 60 : A292 - A292
  • [3] Insulin degludec - Ultra-Long-Acting Basal Insulin
    Heise, T.
    Merker, L.
    Matthaei, S.
    [J]. DIABETES STOFFWECHSEL UND HERZ, 2012, 21 (04): : 231 - 238
  • [4] Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
    Dardano, Angela
    Bianchi, Cristina
    Del Prato, Stefano
    Miccoli, Roberto
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2014, 10 : 465 - 475
  • [5] Insulin detemir and insulin aspart:: a promising basal-bolus regimen for type 2 diabetes
    Raslová, K
    Bogoev, M
    Raz, I
    Leth, G
    Gall, MA
    Hancu, N
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2004, 66 (02) : 193 - 201
  • [6] Insulin degludec: a novel ultra-long-acting basal insulin for use in Type 1 and 2 diabetes
    Meneghini, Luigi F.
    Miranda-Palma, Bresta
    [J]. EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2012, 7 (01) : 9 - 14
  • [7] Efficacy of switching from basal-bolus insulin therapy to twice-daily insulin degludec/insulin aspart co-formulation plus insulin aspart in patients with poorly controlled type 2 diabetes
    Gunes, E.
    Gunes, M.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (14) : 6691 - 6699
  • [8] Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
    Thalange, Nandu
    Deeb, Larry
    Iotova, Violeta
    Kawamura, Tomoyuki
    Klingensmith, Georgeanna
    Philotheou, Areti
    Silverstein, Janet
    Tumini, Stefano
    Ocampo Francisco, Ann-Marie
    Kinduryte, Ona
    Danne, Thomas
    [J]. PEDIATRIC DIABETES, 2015, 16 (03) : 164 - 176
  • [9] Long-term efficacy and safety of insulin degludec in combination with bolus insulin aspart in children and adolescents with type 1 diabetes
    Thalange, N.
    Deeb, L. C.
    Iotova, V.
    Kawamura, T.
    Klingensmith, G. J.
    Philotheou, A.
    Silverstein, J.
    Tumini, S.
    Francisco, A. Ocampo
    Kinduryte, O.
    Danne, T.
    [J]. DIABETOLOGIA, 2014, 57 : S395 - S395
  • [10] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY VERSUS BASAL-BOLUS FULL REGIMEN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN ALGERIA
    Sellam, Y.
    Malek, R.
    Semrouni, M.
    Belhadj, M.
    Zekri, S.
    Brouri, M.
    Arbouche, Z.
    Nouri, N.
    [J]. VALUE IN HEALTH, 2020, 23 : S511 - S511
12345